[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@Bio_Scout map
map posts on X about $rgnx, $abbv, $clsd the most. They currently have XXX followers and XX posts still getting attention that total X engagements in the last XX hours.
Engagements: X #
- X Week XXX -XX%
- X Month XXXXX -XX%
- X Months XXXXXX -XX%
- X Year XXXXXX +117%
Mentions: X #
- X Week X no change
- X Month X -XX%
- X Months XX -XXXX%
- X Year XX +7.70%
Followers: XXX #
- X Week XXX +0.29%
- X Month XXX -XXXX%
- X Months XXX +5.10%
- X Year XXX -XXXX%
CreatorRank: undefined #
Social Influence #
Social category influence stocks XXXX%
Social topic influence $rgnx #9, $abbv 4.35%, $clsd XXXX%
Top accounts mentioned or mentioned by @clearsidebio @regenxbio @aao2025 @biocrystpharma @blco @bauschlomb @clsd @abbvie @jeremyfalmouth
Top assets mentioned AbbVie Inc (ABBV)
Top Social Posts #
Top posts by engagements in the last XX hours
"$RGNX @REGENXBIO @AAO2025 $ABBV $CLSD @clearsidebio LATE BREAKING ABSTRACT AT AAO NEXT WEEK for RGNX: Suprachoroidal Surabgene Lomparvovec (Sura-vec ABBV-RGX-314): First Time 2-Year Results in Non-Proliferative Diabetic Retinopathy Charles C Wykoff MD"
X Link @Bio_Scout 2025-10-08T16:47Z XXX followers, XXX engagements
"$RGNX @REGENXBIO Dr. Khanani patient is 5+ years going strong on Regenxbio gene therapy: "My journey with sura-vec (formerly RGX-314) began during the Phase 1/2 trial where my enrolled patient remains injection-free to this day following a single dose.""
X Link @Bio_Scout 2025-10-08T15:22Z XXX followers, XXX engagements